Diabetic Cardiomyopathy: Role of Cell Death, Exosomes, Fibrosis and Epicardial Adipose Tissue
Abstract
:1. Introduction
2. Cardiomyocyte Cell Death
2.1. Cardiomyocyte Apoptosis
2.2. Cardiomyocytes Pyroptosis
2.3. Autophagy
2.4. Ferroptosis
3. Aquaporins and DCM
4. DCM and Exosomes
5. Cardiac Fibrosis
6. Role of Epicardial Adipose Tissue in DCM
7. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Annicchiarico, A.; Barile, B.; Buccoliero, C.; Nicchia, G.P.; Brunetti, G. Alternative therapeutic strategies in diabetes management. World J. Diabetes 2024, 15, 1142–1161. [Google Scholar] [CrossRef]
- Faienza, M.F.; Pontrelli, P.; Brunetti, G. Type 2 diabetes and bone fragility in children and adults. World J. Diabetes 2022, 13, 900–911. [Google Scholar] [CrossRef]
- Tan, Y.; Zhang, Z.; Zheng, C.; Wintergerst, K.A.; Keller, B.B.; Cai, L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: Preclinical and clinical evidence. Nat. Rev. Cardiol. 2020, 17, 585–607. [Google Scholar] [CrossRef]
- Lopez, J.; Liu, Y.; Butler, J.; Del Prato, S.; Ezekowitz, J.A.; Lam, C.S.P.; Marwick, T.H.; Rosenstock, J.; Tang, W.H.W.; Perfetti, R.; et al. Racial Differences in Diabetic Cardiomyopathy: The ARISE-HF Trial. J. Am. Coll. Cardiol. 2024, 84, 233–243. [Google Scholar] [CrossRef]
- Brunetti, G.; D’Amato, G.; De Santis, S.; Grano, M.; Faienza, M.F. Mechanisms of altered bone remodeling in children with type 1 diabetes. World J. Diabetes 2021, 12, 997–1009. [Google Scholar] [CrossRef] [PubMed]
- Paolillo, S.; Marsico, F.; Prastaro, M.; Renga, F.; Esposito, L.; De Martino, F.; Di Napoli, P.; Esposito, I.; Ambrosio, A.; Ianniruberto, M.; et al. Diabetic Cardiomyopathy. Heart Fail. Clin. 2019, 15, 341–347. [Google Scholar] [CrossRef] [PubMed]
- Khan, S.; Ahmad, S.S.; Kamal, M.A. Diabetic cardiomyopathy: From mechanism to management in a nutshell. Endocr. Metab. Immune Disord.-Drug Targets (Former. Curr. Drug Targets-Immune Endocr. Metab. Disord.) 2021, 21, 268–281. [Google Scholar] [CrossRef]
- Liu, Q.; Wang, S.; Cai, L. Diabetic cardiomyopathy and its mechanisms: Role of oxidative stress and damage. J. Diabetes Investig. 2014, 5, 623–634. [Google Scholar] [CrossRef] [PubMed]
- Wei, J.; Zhao, Y.; Liang, H.; Du, W.; Wang, L. Preliminary evidence for the presence of multiple forms of cell death in diabetes cardiomyopathy. Acta Pharm. Sin. B 2022, 12, 1–17. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.; Hua, Y.; Li, X.; Arslan, I.M.; Zhang, W.; Meng, G. Distinct Types of Cell Death and the Implication in Diabetic Cardiomyopathy. Front. Pharmacol. 2020, 11, 42. [Google Scholar] [CrossRef]
- Dhalla, N.S.; Shah, A.K.; Tappia, P.S. Role of Oxidative Stress in Metabolic and Subcellular Abnormalities in Diabetic Cardiomyopathy. Int. J. Mol. Sci. 2020, 21, 2413. [Google Scholar] [CrossRef]
- Byrne, N.J.; Rajasekaran, N.S.; Abel, E.D.; Bugger, H. Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy. Free Radic. Biol. Med. 2021, 169, 317–342. [Google Scholar] [CrossRef]
- Giacco, F.; Brownlee, M.; Schmidt, A.M. Oxidative Stress and Diabetic Complications. Circ. Res. 2010, 107, 1058–1070. [Google Scholar] [CrossRef]
- Zhang, X.; Ma, X.; Zhao, M.; Zhang, B.; Chi, J.; Liu, W.; Chen, W.; Fu, Y.; Liu, Y.; Yin, X. H2 and H3 relaxin inhibit high glucose-induced apoptosis in neonatal rat ventricular myocytes. Biochimie 2015, 108, 59–67. [Google Scholar] [CrossRef] [PubMed]
- Khanna, S.; Singh, G.B.; Khullar, M. Nitric oxide synthases and diabetic cardiomyopathy. Nitric Oxide 2014, 43, 29–34. [Google Scholar] [CrossRef] [PubMed]
- Li, G.; Yang, L.; Feng, L.; Yang, J.; Li, Y.; An, J.; Li, D.; Xu, Y.; Gao, Y.; Li, J.; et al. Syringaresinol Protects against Type 1 Diabetic Cardiomyopathy by Alleviating Inflammation Responses, Cardiac Fibrosis, and Oxidative Stress. Mol. Nutr. Food Res. 2020, 64, e2000231. [Google Scholar] [CrossRef]
- Song, S.; Ding, Y.; Dai, G.-l.; Zhang, Y.; Xu, M.-t.; Shen, J.-r.; Chen, T.-t.; Chen, Y.; Meng, G.-l. Sirtuin 3 deficiency exacerbates diabetic cardiomyopathy via necroptosis enhancement and NLRP3 activation. Acta Pharmacol. Sin. 2020, 42, 230–241. [Google Scholar] [CrossRef] [PubMed]
- Dia, M.; Gomez, L.; Thibault, H.; Tessier, N.; Leon, C.; Chouabe, C.; Ducreux, S.; Gallo-Bona, N.; Tubbs, E.; Bendridi, N.; et al. Reduced reticulum-mitochondria Ca(2+) transfer is an early and reversible trigger of mitochondrial dysfunctions in diabetic cardiomyopathy. Basic. Res. Cardiol. 2020, 115, 74. [Google Scholar] [CrossRef] [PubMed]
- Torre, E.; Arici, M.; Lodrini, A.M.; Ferrandi, M.; Barassi, P.; Hsu, S.C.; Chang, G.J.; Boz, E.; Sala, E.; Vagni, S.; et al. SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy. Cardiovasc. Res. 2022, 118, 1020–1032. [Google Scholar] [CrossRef]
- Zhao, S.M.; Wang, Y.L.; Guo, C.Y.; Chen, J.L.; Wu, Y.Q. Progressive decay of Ca2+ homeostasis in the development of diabetic cardiomyopathy. Cardiovasc. Diabetol. 2014, 13, 75. [Google Scholar] [CrossRef]
- Chen, Y.; Xin, Y.; Cheng, Y.; Liu, X. Mitochondria-Endoplasmic Reticulum Contacts: The Promising Regulators in Diabetic Cardiomyopathy. Oxid. Med. Cell Longev. 2022, 2022, 2531458. [Google Scholar] [CrossRef]
- Wang, G.; Ma, T.Y.; Huang, K.; Zhong, J.H.; Lu, S.J.; Li, J.J. Role of pyroptosis in diabetic cardiomyopathy: An updated review. Front. Endocrinol. 2023, 14, 1322907. [Google Scholar] [CrossRef] [PubMed]
- Bertheloot, D.; Latz, E.; Franklin, B.S. Necroptosis, pyroptosis and apoptosis: An intricate game of cell death. Cell Mol. Immunol. 2021, 18, 1106–1121. [Google Scholar] [CrossRef] [PubMed]
- Yu, P.; Zhang, X.; Liu, N.; Tang, L.; Peng, C.; Chen, X. Pyroptosis: Mechanisms and diseases. Signal Transduct. Target. Ther. 2021, 6, 128. [Google Scholar] [CrossRef]
- Zhang, Y.; Chen, X.; Gueydan, C.; Han, J. Plasma membrane changes during programmed cell deaths. Cell Res. 2018, 28, 9–21. [Google Scholar] [CrossRef]
- Cai, Z.; Yuan, S.; Luan, X.; Feng, J.; Deng, L.; Zuo, Y.; Li, J. Pyroptosis-Related Inflammasome Pathway: A New Therapeutic Target for Diabetic Cardiomyopathy. Front. Pharmacol. 2022, 13, 842313. [Google Scholar] [CrossRef] [PubMed]
- Li, L.; Luo, W.; Qian, Y.; Zhu, W.; Qian, J.; Li, J.; Jin, Y.; Xu, X.; Liang, G. Luteolin protects against diabetic cardiomyopathy by inhibiting NF-kappaB-mediated inflammation and activating the Nrf2-mediated antioxidant responses. Phytomedicine 2019, 59, 152774. [Google Scholar] [CrossRef] [PubMed]
- Wei, Z.; Jing, Z.; Pinfang, K.; Chao, S.; Shaohuan, Q. Quercetin Inhibits Pyroptosis in Diabetic Cardiomyopathy through the Nrf2 Pathway. J. Diabetes Res. 2022, 2022, 9723632. [Google Scholar] [CrossRef]
- Zeng, C.; Wang, R.; Tan, H. Role of Pyroptosis in Cardiovascular Diseases and its Therapeutic Implications. Int. J. Biol. Sci. 2019, 15, 1345–1357. [Google Scholar] [CrossRef]
- Zhang, H.; Chen, X.; Zong, B.; Yuan, H.; Wang, Z.; Wei, Y.; Wang, X.; Liu, G.; Zhang, J.; Li, S.; et al. Gypenosides improve diabetic cardiomyopathy by inhibiting ROS-mediated NLRP3 inflammasome activation. J. Cell Mol. Med. 2018, 22, 4437–4448. [Google Scholar] [CrossRef]
- Zhang, L.; Ai, C.; Bai, M.; Niu, J.; Zhang, Z. NLRP3 Inflammasome/Pyroptosis: A Key Driving Force in Diabetic Cardiomyopathy. Int. J. Mol. Sci. 2022, 23, 10632. [Google Scholar] [CrossRef]
- Feng, Y.; Xu, W.; Zhang, W.; Wang, W.; Liu, T.; Zhou, X. LncRNA DCRF regulates cardiomyocyte autophagy by targeting miR-551b-5p in diabetic cardiomyopathy. Theranostics 2019, 9, 4558. [Google Scholar] [CrossRef] [PubMed]
- Bhat, A.A.; Goyal, A.; Thapa, R.; Kazmi, I.; Alzarea, S.I.; Singh, M.; Rohilla, S.; Saini, T.K.; Kukreti, N.; Meenakshi, D.U. Uncovering the complex role of interferon-gamma in suppressing type 2 immunity to cancer. Cytokine 2023, 171, 156376. [Google Scholar] [CrossRef] [PubMed]
- Dewanjee, S.; Vallamkondu, J.; Kalra, R.S.; John, A.; Reddy, P.H.; Kandimalla, R. Autophagy in the diabetic heart: A potential pharmacotherapeutic target in diabetic cardiomyopathy. Ageing Res. Rev. 2021, 68, 101338. [Google Scholar] [CrossRef] [PubMed]
- Bhat, A.A.; Gupta, G.; Goyal, A.; Thapa, R.; Almalki, W.H.; Kazmi, I.; Alzarea, S.I.; Kukreti, N.; Sekar, M.; Meenakshi, D.U. Unwinding circular RNA’s role in inflammatory pulmonary diseases. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2024, 397, 2567–2588. [Google Scholar] [CrossRef]
- Kubli, D.A.; Gustafsson, Å.B. Unbreak my heart: Targeting mitochondrial autophagy in diabetic cardiomyopathy. Antioxid. Redox Signal. 2015, 22, 1527–1544. [Google Scholar] [CrossRef]
- Kakoty, V.; Sarathlal, K.; Kaur, P.; Wadhwa, P.; Vishwas, S.; Khan, F.R.; Alhazmi, A.Y.M.; Almasoudi, H.H.; Gupta, G.; Chellappan, D.K. Unraveling the role of glial cell line–derived neurotrophic factor in the treatment of Parkinson’s disease. Neurol. Sci. 2024, 45, 1409–1418. [Google Scholar] [CrossRef]
- Madonna, R.; Moscato, S.; Cufaro, M.C.; Pieragostino, D.; Mattii, L.; Del Boccio, P.; Ghelardoni, S.; Zucchi, R.; De Caterina, R. Empagliflozin inhibits excessive autophagy through the AMPK/GSK3β signalling pathway in diabetic cardiomyopathy. Cardiovasc. Res. 2023, 119, 1175–1189. [Google Scholar] [CrossRef]
- Gulati, N.; Chellappan, D.K.; MacLoughlin, R.; Gupta, G.; Singh, S.K.; Oliver, B.G.; Dua, K.; Dureja, H. Advances in nano-based drug delivery systems for the management of cytokine influx-mediated inflammation in lung diseases. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2023, 397, 3695–3707. [Google Scholar] [CrossRef]
- Guo, Y.; Feng, X.; Wang, D.; Kang, X.; Zhang, L.; Ren, H.; Yuan, G. Long non-coding RNA: A key regulator in the pathogenesis of diabetic cardiomyopathy. Front. Cardiovasc. Med. 2021, 8, 655598. [Google Scholar] [CrossRef]
- Chen, S.; Liu, D.; Zhou, Z.; Qin, S. Role of long non-coding RNA H19 in the development of osteoporosis. Mol. Med. 2021, 27, 122. [Google Scholar] [CrossRef] [PubMed]
- Feng, L.; Yan, Q.; Xu, X. Long non-coding RNA H19 recruits NFYB to activate MBTD1 and regulate doxorubicin resistance in lymphoma cells. Mol. Biotechnol. 2023, 65, 997–1009. [Google Scholar] [CrossRef] [PubMed]
- Alharbi, K.S. Exploring GAS5’s impact on prostate cancer: Recent discoveries and emerging paradigms. Pathol.-Res. Pract. 2023, 251, 154851. [Google Scholar] [CrossRef]
- Filippova, E.A.; Fridman, M.V.; Burdennyy, A.M.; Loginov, V.I.; Pronina, I.V.; Lukina, S.S.; Dmitriev, A.A.; Braga, E.A. Long noncoding RNA GAS5 in breast cancer: Epigenetic mechanisms and biological functions. Int. J. Mol. Sci. 2021, 22, 6810. [Google Scholar] [CrossRef]
- Azizidoost, S.; Ghaedrahmati, F.; Anbiyaee, O.; Ahmad Ali, R.; Cheraghzadeh, M.; Farzaneh, M. Emerging roles for lncRNA-NEAT1 in colorectal cancer. Cancer Cell Int. 2022, 22, 209. [Google Scholar] [CrossRef] [PubMed]
- Bu, F.t.; Wang, A.; Zhu, Y.; You, H.m.; Zhang, Y.f.; Meng, X.m.; Huang, C.; Li, J. LncRNA NEAT1: Shedding light on mechanisms and opportunities in liver diseases. Liver Int. 2020, 40, 2612–2626. [Google Scholar] [CrossRef] [PubMed]
- You, P.; Chen, H.; Han, W.; Deng, J. miR-200a-3p overexpression alleviates diabetic cardiomyopathy injury in mice by regulating autophagy through the FOXO3/Mst1/Sirt3/AMPK axis. PeerJ 2023, 11, e15840. [Google Scholar] [CrossRef]
- Cui, J.; Shu, J. Circulating microRNA trafficking and regulation: Computational principles and practice. Brief. Bioinform. 2020, 21, 1313–1326. [Google Scholar] [CrossRef]
- Fellmann, C.; Hoffmann, T.; Sridhar, V.; Hopfgartner, B.; Muhar, M.; Roth, M.; Lai, D.Y.; Barbosa, I.A.; Kwon, J.S.; Guan, Y. An optimized microRNA backbone for effective single-copy RNAi. Cell Rep. 2013, 5, 1704–1713. [Google Scholar] [CrossRef]
- Break, M.; Khaled, B.; Syed, R.U.; Hussein, W.; Alqarni, S.; Magam, S.M.; Nawaz, M.; Shaikh, S.; Otaibi, A.A.; Masood, N.; et al. Noncoding RNAs as therapeutic targets in autophagy-related diabetic cardiomyopathy. Pathol.-Res. Pract. 2024, 256. [Google Scholar] [CrossRef]
- Costantino, S.; Paneni, F.; Lüscher, T.F.; Cosentino, F. MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart. Eur. Heart J. 2016, 37, 572–576. [Google Scholar] [CrossRef]
- Barrera, G.; Pizzimenti, S.; Ciamporcero, E.S.; Daga, M.; Ullio, C.; Arcaro, A.; Cetrangolo, G.P.; Ferretti, C.; Dianzani, C.; Lepore, A.; et al. Role of 4-Hydroxynonenal-Protein Adducts in Human Diseases. Antioxid. Redox Signal. 2015, 22, 1681–1702. [Google Scholar] [CrossRef]
- Song, Z.; Wang, J.; Zhang, L. Ferroptosis: A New Mechanism in Diabetic Cardiomyopathy. Int. J. Med. Sci. 2024, 21, 612–622. [Google Scholar] [CrossRef] [PubMed]
- Zang, H.; Wu, W.; Qi, L.; Tan, W.; Nagarkatti, P.; Nagarkatti, M.; Wang, X.; Cui, T. Autophagy Inhibition Enables Nrf2 to Exaggerate the Progression of Diabetic Cardiomyopathy in Mice. Diabetes 2020, 69, 2720–2734. [Google Scholar] [CrossRef]
- Zhao, Y.; Li, Y.; Zhang, R.; Wang, F.; Wang, T.; Jiao, Y. The Role of Erastin in Ferroptosis and Its Prospects in Cancer Therapy. OncoTargets Ther. 2020, 13, 5429–5441. [Google Scholar] [CrossRef] [PubMed]
- Ni, T.; Huang, X.; Pan, S.; Lu, Z. Inhibition of the long non-coding RNA ZFAS1 attenuates ferroptosis by sponging miR-150-5p and activates CCND2 against diabetic cardiomyopathy. J. Cell. Mol. Med. 2021, 25, 9995–10007. [Google Scholar] [CrossRef] [PubMed]
- Papadopoulos, M.C.; Saadoun, S. Key roles of aquaporins in tumor biology. Biochim. Biophys. Acta (BBA)-Biomembr. 2015, 1848, 2576–2583. [Google Scholar] [CrossRef]
- Shangzu, Z.; Dingxiong, X.; ChengJun, M.; Yan, C.; Yangyang, L.; Zhiwei, L.; Ting, Z.; Zhiming, M.; Yiming, Z.; Liying, Z.; et al. Aquaporins: Important players in the cardiovascular pathophysiology. Pharmacol. Res. 2022, 183, 106363. [Google Scholar] [CrossRef] [PubMed]
- Frustaci, A.; Letizia, C.; Chimenti, C.; Verardo, R.; Alfarano, M.; Scialla, R.; Bagnato, G.; Miraldi, F.; Sansone, L.; Russo, M.A. Myocardial Aldosterone Receptor and Aquaporin 1 Up-Regulation Is Associated with Cardiomyocyte Remodeling in Human Heart Failure. J. Clin. Med. 2021, 10, 4854. [Google Scholar] [CrossRef]
- Li, L.; Weng, Z.; Yao, C.; Song, Y.; Ma, T. Aquaporin-1 Deficiency Protects Against Myocardial Infarction by Reducing Both Edema and Apoptosis in Mice. Sci. Rep. 2015, 5, 13807. [Google Scholar] [CrossRef]
- Eltobshy, S.A.G.; Messiha, R.; Metias, E.; Sarhan, M.; El-Gamal, R.; El-Shaieb, A.; Ghalwash, M. Effect of SGLT2 Inhibitor on Cardiomyopathy in a Rat Model of T2DM: Possible involvement of Cardiac Aquaporins. Tissue Cell 2023, 85, 102200. [Google Scholar] [CrossRef] [PubMed]
- Mani, S.; Gurusamy, N.; Ulaganathan, T.; Paluck, A.J.; Ramalingam, S.; Rajasingh, J. Therapeutic potentials of stem cell–derived exosomes in cardiovascular diseases. Exp. Biol. Med. 2023, 248, 434–444. [Google Scholar] [CrossRef] [PubMed]
- Mishra, A.; Bharti, P.S.; Rani, N.; Nikolajeff, F.; Kumar, S. A tale of exosomes and their implication in cancer. Biochim. Biophys. Acta (BBA)-Rev. Cancer 2023, 1878, 188908. [Google Scholar] [CrossRef]
- Mondal, J.; Pillarisetti, S.; Junnuthula, V.; Saha, M.; Hwang, S.R.; Park, I.-k.; Lee, Y.-k. Hybrid exosomes, exosome-like nanovesicles and engineered exosomes for therapeutic applications. J. Control. Release 2023, 353, 1127–1149. [Google Scholar] [CrossRef]
- Saravanan, P.B.; Kalivarathan, J.; Khan, F.; Shah, R.; Levy, M.F.; Kanak, M.A. Exosomes in transplantation: Role in allograft rejection, diagnostic biomarker, and therapeutic potential. Life Sci. 2023, 324, 121722. [Google Scholar] [CrossRef]
- Yao, J.; Chen, Y.; Lin, Z. Exosomes: Mediators in microenvironment of colorectal cancer. Int. J. Cancer 2023, 153, 904–917. [Google Scholar] [CrossRef] [PubMed]
- Ye, H.; Tan, L.; Tu, C.; Min, L. Exosomes in sarcoma: Prospects for clinical applications. Crit. Rev. Oncol./Hematol. 2023, 181, 103895. [Google Scholar] [CrossRef] [PubMed]
- Zhang, M.; Hu, S.; Liu, L.; Dang, P.; Liu, Y.; Sun, Z.; Qiao, B.; Wang, C. Engineered exosomes from different sources for cancer-targeted therapy. Signal Transduct. Target. Ther. 2023, 8, 124. [Google Scholar] [CrossRef] [PubMed]
- Xu, Z.; Chen, Y.; Ma, L.; Chen, Y.; Liu, J.; Guo, Y.; Yu, T.; Zhang, L.; Zhu, L.; Shu, Y. Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment. Mol. Ther. 2022, 30, 3133–3154. [Google Scholar] [CrossRef]
- An, Y.; Lin, S.; Tan, X.; Zhu, S.; Nie, F.; Zhen, Y.; Gu, L.; Zhang, C.; Wang, B.; Wei, W.; et al. Exosomes from adipose-derived stem cells and application to skin wound healing. Cell Prolif. 2021, 54, e12993. [Google Scholar] [CrossRef]
- He, Y.; Li, Y.; Zhai, Z.; Liu, P.; Nie, L.; Zheng, Y.; Hou, J.; Huo, W.; Mao, Z.; Zhang, Z.; et al. Relationship of miRNA-126 and miRNA-122 expression with type 2 diabetes mellitus and related glucose metabolism parameters: A systematic review and meta-analysis. Exp. Ther. Med. 2022, 24, 652. [Google Scholar] [CrossRef] [PubMed]
- Hu, Y.; Rao, S.-S.; Wang, Z.-X.; Cao, J.; Tan, Y.-J.; Luo, J.; Li, H.-M.; Zhang, W.-S.; Chen, C.-Y.; Xie, H. Exosomes from human umbilical cord blood accelerate cutaneous wound healing through miR-21-3p-mediated promotion of angiogenesis and fibroblast function. Theranostics 2018, 8, 169–184. [Google Scholar] [CrossRef] [PubMed]
- Jiang, L.; Dong, H.; Cao, H.; Ji, X.; Luan, S.; Liu, J. Exosomes in Pathogenesis, Diagnosis, and Treatment of Alzheimer’s Disease. Med. Sci. Monit. 2019, 25, 3329–3335. [Google Scholar] [CrossRef] [PubMed]
- Liu, J.; Jiang, F.; Jiang, Y.; Wang, Y.; Li, Z.; Shi, X.; Zhu, Y.; Wang, H.; Zhang, Z. Roles of Exosomes in Ocular Diseases. Int. J. Nanomed. 2020, 15, 10519–10538. [Google Scholar] [CrossRef]
- Liu, X.; Miao, J.; Wang, C.; Zhou, S.; Chen, S.; Ren, Q.; Hong, X.; Wang, Y.; Hou, F.F.; Zhou, L.; et al. Tubule-derived exosomes play a central role in fibroblast activation and kidney fibrosis. Kidney Int. 2020, 97, 1181–1195. [Google Scholar] [CrossRef]
- Soares Martins, T.; Trindade, D.; Vaz, M.; Campelo, I.; Almeida, M.; Trigo, G.; da Cruz e Silva, O.A.B.; Henriques, A.G. Diagnostic and therapeutic potential of exosomes in Alzheimer’s disease. J. Neurochem. 2020, 156, 162–181. [Google Scholar] [CrossRef]
- Zhang, X.; Wang, J.; Zhang, J.; Tan, Y.; Li, Y.; Peng, Z. Exosomes Highlight Future Directions in the Treatment of Acute Kidney Injury. Int. J. Mol. Sci. 2023, 24, 15568. [Google Scholar] [CrossRef]
- Liang, G.; Zhu, Y.; Ali, D.J.; Tian, T.; Xu, H.; Si, K.; Sun, B.; Chen, B.; Xiao, Z. Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer. J. Nanobiotechnol. 2020, 18, 10. [Google Scholar] [CrossRef]
- Batrakova, E.V.; Kim, M.S. Using exosomes, naturally-equipped nanocarriers, for drug delivery. J. Control. Release 2015, 219, 396–405. [Google Scholar] [CrossRef] [PubMed]
- Liang, Y.; Duan, L.; Lu, J.; Xia, J. Engineering exosomes for targeted drug delivery. Theranostics 2021, 11, 3183–3195. [Google Scholar] [CrossRef]
- Rehman, F.U.; Liu, Y.; Zheng, M.; Shi, B. Exosomes based strategies for brain drug delivery. Biomaterials 2023, 293, 121949. [Google Scholar] [CrossRef] [PubMed]
- Fang, Y.; Ni, J.; Wang, Y.-S.; Zhao, Y.; Jiang, L.-Q.; Chen, C.; Zhang, R.-D.; Fang, X.; Wang, P.; Pan, H.-F. Exosomes as biomarkers and therapeutic delivery for autoimmune diseases: Opportunities and challenges. Autoimmun. Rev. 2023, 22, 103260. [Google Scholar] [CrossRef] [PubMed]
- Ren, Y.; Zhang, S.; Wang, Y.; Jacobson, D.S.; Reisdorf, R.L.; Kuroiwa, T.; Behfar, A.; Moran, S.L.; Steinmann, S.P.; Zhao, C. Effects of purified exosome product on rotator cuff tendon-bone healing in vitro and in vivo. Biomaterials 2021, 276, 121019. [Google Scholar] [CrossRef] [PubMed]
- Xie, R.; Zeng, X.; Yan, H.; Huang, X.; Deng, C. Effects and Mechanisms of Exosomes from Different Sources in Cerebral Ischemia. Cells 2022, 11, 3623. [Google Scholar] [CrossRef]
- Guo, J.; Yang, X.; Chen, J.; Wang, C.; Sun, Y.; Yan, C.; Ren, S.; Xiong, H.; Xiang, K.; Zhang, M.; et al. Exosomal miR-125b-5p derived from adipose-derived mesenchymal stem cells enhance diabetic hindlimb ischemia repair via targeting alkaline ceramidase 2. J. Nanobiotechnol. 2023, 21, 189. [Google Scholar] [CrossRef]
- Ilaltdinov, A.W.; Gong, Y.; Leong, D.J.; Gruson, K.I.; Zheng, D.; Fung, D.T.; Sun, L.; Sun, H.B. Advances in the development of gene therapy, noncoding RNA, and exosome-based treatments for tendinopathy. Ann. N. Y. Acad. Sci. 2020, 1490, 3–12. [Google Scholar] [CrossRef]
- Wang, C.; Wang, M.; Xu, T.; Zhang, X.; Lin, C.; Gao, W.; Xu, H.; Lei, B.; Mao, C. Engineering Bioactive Self-Healing Antibacterial Exosomes Hydrogel for Promoting Chronic Diabetic Wound Healing and Complete Skin Regeneration. Theranostics 2019, 9, 65–76. [Google Scholar] [CrossRef]
- Cui, M.; Han, Y.; Yang, J.; Li, G.; Yang, C. A narrative review of the research status of exosomes in cardiovascular disease. Ann. Palliat. Med. 2022, 11, 363–377. [Google Scholar] [CrossRef]
- Nandi, S.S.; Mishra, P.K. Targeting miRNA for Therapy of Juvenile and Adult Diabetic Cardiomyopathy. Adv. Exp. Med. Biol. 2018, 1056, 47–59. [Google Scholar]
- Sanganalmath, S.K.; Dubey, S.; Veeranki, S.; Narisetty, K.; Krishnamurthy, P. The interplay of inflammation, exosomes and Ca2+ dynamics in diabetic cardiomyopathy. Cardiovasc. Diabetol. 2023, 22, 37. [Google Scholar] [CrossRef]
- Tao, L.; Shi, J.; Yang, X.; Yang, L.; Hua, F. The Exosome: A New Player in Diabetic Cardiomyopathy. J. Cardiovasc. Transl. Res. 2018, 12, 62–67. [Google Scholar] [CrossRef] [PubMed]
- Zamani, P.; Fereydouni, N.; Butler, A.E.; Navashenaq, J.G.; Sahebkar, A. The therapeutic and diagnostic role of exosomes in cardiovascular diseases. Trends Cardiovasc. Med. 2019, 29, 313–323. [Google Scholar] [CrossRef] [PubMed]
- Chaturvedi, P.; Kalani, A.; Medina, I.; Familtseva, A.; Tyagi, S.C. Cardiosome mediated regulation of MMP9 in diabetic heart: Role of mir29b and mir455 in exercise. J. Cell. Mol. Med. 2015, 19, 2153–2161. [Google Scholar] [CrossRef] [PubMed]
- Hirai, K.; Ousaka, D.; Fukushima, Y.; Kondo, M.; Eitoku, T.; Shigemitsu, Y.; Hara, M.; Baba, K.; Iwasaki, T.; Kasahara, S.; et al. Cardiosphere-derived exosomal microRNAs for myocardial repair in pediatric dilated cardiomyopathy. Sci. Transl. Med. 2020, 12, eabb3336. [Google Scholar] [CrossRef] [PubMed]
- Gan, L.; Xie, D.; Liu, J.; Bond Lau, W.; Christopher, T.A.; Lopez, B.; Zhang, L.; Gao, E.; Koch, W.; Ma, X.-L.; et al. Small Extracellular Microvesicles Mediated Pathological Communications Between Dysfunctional Adipocytes and Cardiomyocytes as a Novel Mechanism Exacerbating Ischemia/Reperfusion Injury in Diabetic Mice. Circulation 2020, 141, 968–983. [Google Scholar] [CrossRef]
- Ni, J.; Sun, Y.; Liu, Z. The Potential of Stem Cells and Stem Cell-Derived Exosomes in Treating Cardiovascular Diseases. J. Cardiovasc. Transl. Res. 2018, 12, 51–61. [Google Scholar] [CrossRef]
- Yu, B.; Kim, H.W.; Gong, M.; Wang, J.; Millard, R.W.; Wang, Y.; Ashraf, M.; Xu, M. Exosomes secreted from GATA-4 overexpressing mesenchymal stem cells serve as a reservoir of anti-apoptotic microRNAs for cardioprotection. Int. J. Cardiol. 2015, 182, 349–360. [Google Scholar] [CrossRef]
- Huang-Doran, I.; Zhang, C.-Y.; Vidal-Puig, A. Extracellular Vesicles: Novel Mediators of Cell Communication In Metabolic Disease. Trends Endocrinol. Metab. 2017, 28, 3–18. [Google Scholar] [CrossRef]
- Lawson, C.; Vicencio, J.M.; Yellon, D.M.; Davidson, S.M. Microvesicles and exosomes: New players in metabolic and cardiovascular disease. J. Endocrinol. 2016, 228, R57–R71. [Google Scholar] [CrossRef]
- Sahoo, S.; Emanueli, C. Exosomes in Diabetic Cardiomyopathy: The Next-Generation Therapeutic Targets? Diabetes 2016, 65, 2829–2831. [Google Scholar] [CrossRef]
- Wang, X.; Gu, H.; Huang, W.; Peng, J.; Li, Y.; Yang, L.; Qin, D.; Essandoh, K.; Wang, Y.; Peng, T.; et al. Hsp20-Mediated Activation of Exosome Biogenesis in Cardiomyocytes Improves Cardiac Function and Angiogenesis in Diabetic Mice. Diabetes 2016, 65, 3111–3128. [Google Scholar] [CrossRef] [PubMed]
- Wang, X.; Huang, W.; Liu, G.; Cai, W.; Millard, R.W.; Wang, Y.; Chang, J.; Peng, T.; Fan, G.-C. Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer of miR-320 into endothelial cells. J. Mol. Cell. Cardiol. 2014, 74, 139–150. [Google Scholar] [CrossRef] [PubMed]
- Shi, R.; Zhao, L.; Cai, W.; Wei, M.; Zhou, X.; Yang, G.; Yuan, L. Maternal exosomes in diabetes contribute to the cardiac development deficiency. Biochem. Biophys. Res. Commun. 2017, 483, 602–608. [Google Scholar] [CrossRef] [PubMed]
- Das, S.; Halushka, M.K. Extracellular vesicle microRNA transfer in cardiovascular disease. Cardiovasc. Pathol. 2015, 24, 199–206. [Google Scholar] [CrossRef]
- Loyer, X.; Vion, A.-C.; Tedgui, A.; Boulanger, C.M. Microvesicles as Cell–Cell Messengers in Cardiovascular Diseases. Circ. Res. 2014, 114, 345–353. [Google Scholar] [CrossRef] [PubMed]
- Vrijsen, K.R.; Sluijter, J.P.G.; Schuchardt, M.W.L.; Van Balkom, B.W.M.; Noort, W.A.; Chamuleau, S.A.J.; Doevendans, P.A.F.M. Cardiomyocyte progenitor cell-derived exosomes stimulate migration of endothelial cells. J. Cell. Mol. Med. 2010, 14, 1064–1070. [Google Scholar] [CrossRef]
- Atlas, S.A. The Renin-Angiotensin Aldosterone System: Pathophysiological Role and Pharmacologic Inhibition. J. Manag. Care Pharm. 2007, 13 (Suppl. B), 9–20. [Google Scholar] [CrossRef]
- Busson, P.; Garcia, N.A.; Ontoria-Oviedo, I.; González-King, H.; Diez-Juan, A.; Sepúlveda, P. Glucose Starvation in Cardiomyocytes Enhances Exosome Secretion and Promotes Angiogenesis in Endothelial Cells. PLoS ONE 2015, 10, e0138849. [Google Scholar] [CrossRef]
- Huo, J.-L.; Feng, Q.; Pan, S.; Fu, W.-J.; Liu, Z.; Liu, Z. Diabetic cardiomyopathy: Early diagnostic biomarkers, pathogenetic mechanisms, and therapeutic interventions. Cell Death Discov. 2023, 9, 256. [Google Scholar] [CrossRef]
- Tuleta, I.; Frangogiannis, N.G. Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities. Adv. Drug Deliv. Rev. 2021, 176, 113904. [Google Scholar] [CrossRef]
- Frangogiannis, N.G. The Extracellular Matrix in Ischemic and Nonischemic Heart Failure. Circ. Res. 2019, 125, 117–146. [Google Scholar] [CrossRef] [PubMed]
- Frangogiannis, N.G. Pathophysiology of Myocardial Infarction. Compr. Physiol. 2015, 5, 1841–1875. [Google Scholar] [PubMed]
- Kurose, H. Cardiac Fibrosis and Fibroblasts. Cells 2021, 10, 1716. [Google Scholar] [CrossRef]
- Singh, V.P.; Baker, K.M.; Kumar, R. Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: Role in extracellular matrix production. Am. J. Physiol.-Heart Circ. Physiol. 2008, 294, H1675–H1684. [Google Scholar] [CrossRef]
- Lorenzo, O.; Picatoste, B.; Ares-Carrasco, S.; Ramírez, E.; Egido, J.; Tuñón, J. Potential Role of Nuclear Factor κB in Diabetic Cardiomyopathy. Mediat. Inflamm. 2011, 2011, 652097. [Google Scholar] [CrossRef] [PubMed]
- Aronson, D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J. Hypertens. 2003, 21, 3–12. [Google Scholar] [CrossRef]
- Jia, G.; Whaley-Connell, A.; Sowers, J.R. Diabetic cardiomyopathy: A hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia 2017, 61, 21–28. [Google Scholar] [CrossRef]
- Jia, G.; DeMarco, V.G.; Sowers, J.R. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat. Rev. Endocrinol. 2015, 12, 144–153. [Google Scholar] [CrossRef]
- Batista, J.P.T.; Faria, A.O.V.d.; Ribeiro, T.F.S.; Simões e Silva, A.C. The Role of Renin–Angiotensin System in Diabetic Cardiomyopathy: A Narrative Review. Life 2023, 13, 1598. [Google Scholar] [CrossRef]
- Duerrschmid, C.; Crawford, J.R.; Reineke, E.; Taffet, G.E.; Trial, J.; Entman, M.L.; Haudek, S.B. TNF receptor 1 signaling is critically involved in mediating angiotensin-II-induced cardiac fibrosis. J. Mol. Cell. Cardiol. 2013, 57, 59–67. [Google Scholar] [CrossRef]
- Iwata, M.; Cowling, R.T.; Gurantz, D.; Moore, C.; Zhang, S.; Yuan, J.X.J.; Greenberg, B.H. Angiotensin-(1–7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am. J. Physiol.-Heart Circ. Physiol. 2005, 289, H2356–H2363. [Google Scholar] [CrossRef] [PubMed]
- Westermann, D.; Rutschow, S.; Jäger, S.; Linderer, A.; Anker, S.; Riad, A.; Unger, T.; Schultheiss, H.-P.; Pauschinger, M.; Tschöpe, C. Contributions of Inflammation and Cardiac Matrix Metalloproteinase Activity to Cardiac Failure in Diabetic Cardiomyopathy. Diabetes 2007, 56, 641–646. [Google Scholar] [CrossRef]
- Frangogiannis, N.G. Transforming growth factor–β in tissue fibrosis. J. Exp. Med. 2020, 217, e20190103. [Google Scholar] [CrossRef]
- Xu, Z.; Sun, J.; Tong, Q.; Lin, Q.; Qian, L.; Park, Y.; Zheng, Y. The Role of ERK1/2 in the Development of Diabetic Cardiomyopathy. Int. J. Mol. Sci. 2016, 17, 2001. [Google Scholar] [CrossRef]
- Wu, L.; Derynck, R. Essential Role of TGF-β Signaling in Glucose-Induced Cell Hypertrophy. Dev. Cell 2009, 17, 35–48. [Google Scholar] [CrossRef] [PubMed]
- Yue, Y.; Meng, K.; Pu, Y.; Zhang, X. Transforming growth factor beta (TGF-β) mediates cardiac fibrosis and induces diabetic cardiomyopathy. Diabetes Res. Clin. Pract. 2017, 133, 124–130. [Google Scholar] [CrossRef] [PubMed]
- Qin, J.; Tan, Y.; Han, Y.; Yu, L.; Liu, S.; Zhao, S.; Wan, H.; Qu, S. Interplay Between TGF-β Signaling and MicroRNA in Diabetic Cardiomyopathy. Cardiovasc. Drugs Ther. 2023; in press. [Google Scholar] [CrossRef] [PubMed]
- Li, Q.; Yao, Y.; Shi, S.; Zhou, M.; Zhou, Y.; Wang, M.; Chiu, J.J.; Huang, Z.; Zhang, W.; Liu, M.; et al. Inhibition of miR-21 alleviated cardiac perivascular fibrosis via repressing EndMT in T1DM. J. Cell. Mol. Med. 2019, 24, 910–920. [Google Scholar] [CrossRef]
- Zhang, D.; Cui, Y.; Li, B.; Luo, X.; Li, B.; Tang, Y. miR-155 regulates high glucose-induced cardiac fibrosis via the TGF-β signaling pathway. Mol. BioSyst. 2017, 13, 215–224. [Google Scholar] [CrossRef]
- Iacobellis, G.; Corradi, D.; Sharma, A.M. Epicardial adipose tissue: Anatomic, biomolecular and clinical relationships with the heart. Nat. Clin. Pract. Cardiovasc. Med. 2005, 2, 536–543. [Google Scholar] [CrossRef]
- Antonopoulos, A.S.; Antoniades, C. The role of epicardial adipose tissue in cardiac biology: Classic concepts and emerging roles. J. Physiol. 2017, 595, 3907–3917. [Google Scholar] [CrossRef] [PubMed]
- Aldiss, P.; Davies, G.; Woods, R.; Budge, H.; Sacks, H.S.; Symonds, M.E. ‘Browning’the cardiac and peri-vascular adipose tissues to modulate cardiovascular risk. Int. J. Cardiol. 2017, 228, 265–274. [Google Scholar] [CrossRef] [PubMed]
- Iacobellis, G. Epicardial adipose tissue in contemporary cardiology. Nat. Rev. Cardiol. 2022, 19, 593–606. [Google Scholar] [CrossRef] [PubMed]
- Lamb, H.J. Visceral and Ectopic Fat: Risk Factors for Type 2 Diabetes, Atherosclerosis, and Cardiovascular Disease; Elsevier: Amsterdam, The Netherlands, 2022. [Google Scholar]
- Sacks, H.S.; Fain, J.N.; Holman, B.; Cheema, P.; Chary, A.; Parks, F.; Karas, J.; Optican, R.; Bahouth, S.W.; Garrett, E. Uncoupling protein-1 and related messenger ribonucleic acids in human epicardial and other adipose tissues: Epicardial fat functioning as brown fat. J. Clin. Endocrinol. Metab. 2009, 94, 3611–3615. [Google Scholar] [CrossRef]
- Moreno-Santos, I.; Pérez-Belmonte, L.M.; Macías-González, M.; Mataró, M.J.; Castellano, D.; López-Garrido, M.; Porras-Martín, C.; Sánchez-Fernández, P.L.; Gómez-Doblas, J.J.; Cardona, F. Type 2 diabetes is associated with decreased PGC1α expression in epicardial adipose tissue of patients with coronary artery disease. J. Transl. Med. 2016, 14, 243. [Google Scholar] [CrossRef]
- Lodewijks, F.; McKinsey, T.A.; Robinson, E.L. Fat-to-heart crosstalk in health and disease. Front. Genet. 2023, 14, 990155. [Google Scholar] [CrossRef]
- Yang, H.; Xiong, B.; Xiong, T.; Wang, D.; Yu, W.; Liu, B.; She, Q. Identification of key genes and mechanisms of epicardial adipose tissue in patients with diabetes through bioinformatic analysis. Front. Cardiovasc. Med. 2022, 9, 927397. [Google Scholar] [CrossRef]
- Al-Talabany, S.; Mordi, I.; Graeme Houston, J.; Colhoun, H.M.; Weir-McCall, J.R.; Matthew, S.Z.; Looker, H.C.; Levin, D.; Belch, J.J.; Dove, F. Epicardial adipose tissue is related to arterial stiffness and inflammation in patients with cardiovascular disease and type 2 diabetes. BMC Cardiovasc. Disord. 2018, 18, 31. [Google Scholar] [CrossRef]
- Chowdhary, A.; Thirunavukarasu, S.; Jex, N.; Coles, L.; Bowers, C.; Sengupta, A.; Swoboda, P.; Witte, K.; Cubbon, R.; Xue, H. Coronary microvascular function and visceral adiposity in patients with normal body weight and type 2 diabetes. Obesity 2022, 30, 1079–1090. [Google Scholar] [CrossRef]
- Homsi, R.; Sprinkart, A.M.; Gieseke, J.; Meier-Schroers, M.; Yuecel, S.; Fischer, S.; Nadal, J.; Dabir, D.; Luetkens, J.A.; Kuetting, D.L. Cardiac magnetic resonance based evaluation of aortic stiffness and epicardial fat volume in patients with hypertension, diabetes mellitus, and myocardial infarction. Acta Radiol. 2018, 59, 65–71. [Google Scholar] [CrossRef]
- Huang, S.; Li, Y.; Jiang, L.; Ren, Y.; Wang, J.; Shi, K.; Yan, W.F.; Qian, W.L.; Yang, Z.G. Impact of type 2 diabetes mellitus on epicardial adipose tissue and myocardial microcirculation by MRI in postmenopausal women. J. Magn. Reson. Imaging 2022, 56, 1404–1413. [Google Scholar] [CrossRef] [PubMed]
- Levelt, E.; Pavlides, M.; Banerjee, R.; Mahmod, M.; Kelly, C.; Sellwood, J.; Ariga, R.; Thomas, S.; Francis, J.; Rodgers, C. Ectopic and visceral fat deposition in lean and obese patients with type 2 diabetes. J. Am. Coll. Cardiol. 2016, 68, 53–63. [Google Scholar] [CrossRef] [PubMed]
- Kotha, S.; Plein, S.; Greenwood, J.P.; Levelt, E. Role of epicardial adipose tissue in diabetic cardiomyopathy through the lens of cardiovascular magnetic resonance imaging–a narrative review. Ther. Adv. Endocrinol. Metab. 2024, 15, 20420188241229540. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Galeone, A.; Annicchiarico, A.; Buccoliero, C.; Barile, B.; Luciani, G.B.; Onorati, F.; Nicchia, G.P.; Brunetti, G. Diabetic Cardiomyopathy: Role of Cell Death, Exosomes, Fibrosis and Epicardial Adipose Tissue. Int. J. Mol. Sci. 2024, 25, 9481. https://doi.org/10.3390/ijms25179481
Galeone A, Annicchiarico A, Buccoliero C, Barile B, Luciani GB, Onorati F, Nicchia GP, Brunetti G. Diabetic Cardiomyopathy: Role of Cell Death, Exosomes, Fibrosis and Epicardial Adipose Tissue. International Journal of Molecular Sciences. 2024; 25(17):9481. https://doi.org/10.3390/ijms25179481
Chicago/Turabian StyleGaleone, Antonella, Alessia Annicchiarico, Cinzia Buccoliero, Barbara Barile, Giovanni Battista Luciani, Francesco Onorati, Grazia Paola Nicchia, and Giacomina Brunetti. 2024. "Diabetic Cardiomyopathy: Role of Cell Death, Exosomes, Fibrosis and Epicardial Adipose Tissue" International Journal of Molecular Sciences 25, no. 17: 9481. https://doi.org/10.3390/ijms25179481